Peptide legality in the EU: 27 countries, 27 rulebooks
Americans treat the FDA crackdown as the worst thing that can happen to peptide access. Europe looks like the opposite, because you can buy almost anything online and most of the time nobody stops you. That reading is wrong. The EU is not outside the regulatory framework. It sits between 27 of them, and a patchwork of 27 national rules is harder to navigate than one strict federal one, not easier.
Start with what didn't happen. When the US eased its stance on compounded peptides in April 2026, nothing equivalent moved in Europe. The EMA path runs 18 to 24 months behind. Retatrutide has no EMA approval and isn't expected until roughly 2027-2028. BPC-157, TB-500, CJC-Ipamorelin and Tesamorelin have no EMA authorization either, so they circulate as research-use-only products with no legal route to a patient for therapeutic use. The only compounds a European can get through a real prescription today are the EMA-approved GLP-1s, semaglutide and tirzepatide, under their brand names.
So the real map isn't legal versus illegal. It's which of the 27 national enforcement regimes you happen to be standing in. Here is how the ones that matter actually differ.
France: the strictest, and it's not close
Selling peptides in France is exercice illegal de la pharmacie, the illegal practice of pharmacy. That is a criminal offense, not a regulatory infraction, and the "for research only" label carries no weight against it. ANSM, the French medicines regulator, does not recognize the research framing. Customs can seize and destroy an incoming order without giving you a route to appeal.
What you can get legally is narrow. Brand-name GLP-1s (liraglutide, dulaglutide, semaglutide, tirzepatide) are available by prescription. Everything else runs through the gray market. Community reports put customs seizure on declared peptide shipments into France around 50%, the highest in the bloc.
The oddity is that "registered French vendors" exist anyway, with real company registrations, mainstream card processors, and fast domestic shipping. The paperwork does not cure the underlying offense. They operate because the market is still small enough not to be worth prosecuting, which is a fragile footing that resets the day enforcement decides to move.
Switzerland: the one clean legal route
Switzerland is the best case in Europe by a wide margin, and it comes down to one word: magistral. Swissmedic recognizes magistral compounding under specific pharmacist licenses, which means a licensed pharmacy can compound a peptide on a per-patient prescription basis, legally, today. Compounded GLP-1s, BPC-157, TB-500 and CJC-Ipamorelin are all reachable through that chain if you have a prescriber willing to write the script.
Enforcement matches the clarity. Community reports put Swiss customs seizure around 3%, versus roughly 50% in France. The catch is price. A compounded GLP-1 through a Swiss pharmacy runs 600 to 1,500 euros a month depending on dose and clinic margin, and premium longevity clinics charge five figures for full bespoke protocols. The legal route exists. It is just expensive.
One trap worth flagging: a Swiss prescription does not transfer to another country's pharmacies. Some EU residents fly in, consult, fill in Switzerland, then carry the product home personally. Whether that is legal depends entirely on the home country, so check before you assume.
Germany: workable but narrow
Germany is the largest longevity-adjacent market in the EU, and it has a real prescription path. Under section 21 AMG, a private prescription can cover off-label semaglutide and tirzepatide. It works, but the lane is narrow and the culture is risk-averse. Peptides are barely a topic even in ordinary gyms, most pharmacists won't touch anything beyond brand-name GLP-1s, and enforcement on inbound shipments is among the stricter in Europe.
Netherlands: the operator's base
The Netherlands does not have looser rules for the buyer. It has better plumbing for a licensed operator. Its pharmaceutical distribution law is well-established, magistral compounding through KNMP-licensed pharmacies is a recognized route, and the Farmatec licensing path makes legal import into the EU achievable. Rotterdam customs is predictable. For an individual it is not a permissive jurisdiction. For a company trying to build a legal supply chain, it is the most credible base in the bloc.
The UK: a separate game post-Brexit
Post-Brexit, the UK runs on its own rules and does not share EU pharmacy mutual recognition cleanly. The upside is a mature telehealth market: CQC-registered clinics prescribe semaglutide through legitimate channels at roughly 150 to 250 pounds a month. Treat the UK as parallel to the EU, not part of it.
Eastern Europe: where the gray market is based
Most of the research-use-only vendors serving Europe operate out of Eastern Europe, Poland and Czechia especially. The reason is not legality. Those regulators concentrate enforcement on human medicines rather than research-labeled chemical supply, so the vendors live in the enforcement gap and bet the regulator doesn't catch up. The EU's direction of travel is tightening, so that clock is running.
What this means if you're buying
The one thing to internalize: nearly every non-GLP-1 peptide sold to a European consumer today moves outside a legal channel, no matter how legitimate the vendor's website looks. A registered company, a working card checkout, and a clean certificate of analysis do not change the legal status of the transaction. In most of the EU they change your odds of getting caught, not the law.
If you want to stay inside the lines, the honest set of options is small: brand-name GLP-1s by prescription anywhere in the EU, or the Swiss magistral-compounding route if you can afford it. Everything else is a gray-zone bet whose odds depend on which of the 27 countries you are standing in.
Sourcing safely is a separate problem from sourcing legally, and most people get burned on the first one. Start with how to vet a peptide source. For the mechanics of how the gray market actually separates people from their money, read how peptide scams actually work and why your "USA-made" peptide was made in China. New pieces land in the feed.